Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 236

1.

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD, Levine MM.

J Infect Dis. 2004 Nov 15;190(10):1745-54. Epub 2004 Oct 19. Erratum in: J Infect Dis. 2005 Jun 15;191(12):2161.

PMID:
15499528
[PubMed - indexed for MEDLINE]
Free Article
2.

Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP, Levine MM.

Infect Immun. 1996 Nov;64(11):4542-8.

PMID:
8890204
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.

Ranallo RT, Thakkar S, Chen Q, Venkatesan MM.

Vaccine. 2007 Mar 8;25(12):2269-78. Epub 2006 Dec 20.

PMID:
17229494
[PubMed - indexed for MEDLINE]
4.

Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.

Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML.

Vaccine. 2009 Feb 18;27(8):1184-91. doi: 10.1016/j.vaccine.2008.12.021. Epub 2009 Jan 9.

PMID:
19135496
[PubMed - indexed for MEDLINE]
5.

Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.

Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM.

Infect Immun. 2000 Mar;68(3):1034-9.

PMID:
10678904
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults.

Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL.

Infect Immun. 2002 Apr;70(4):2016-21.

PMID:
11895966
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL.

Infect Immun. 2004 Feb;72(2):923-30.

PMID:
14742537
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.

Simon JK, Maciel M Jr, Weld ED, Wahid R, Pasetti MF, Picking WL, Kotloff KL, Levine MM, Sztein MB.

Clin Immunol. 2011 May;139(2):185-92. doi: 10.1016/j.clim.2011.02.003. Epub 2011 Mar 8.

PMID:
21388888
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.

McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3735-45. Epub 2005 Jul 21.

PMID:
16095766
[PubMed - indexed for MEDLINE]
10.

Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media.

Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, Nataro JP, Blackwelder WC, Barry EM, Picking W, Levine MM.

Hum Vaccin. 2007 Nov-Dec;3(6):268-75. Epub 2007 Jul 15.

PMID:
17938573
[PubMed - indexed for MEDLINE]
Free Article
11.

Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.

Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N, Islam MS, Sohel BM, Rahman M, Venkatesan M, Hale TL, Isenbarger DW, Sansonetti PJ, Black RE, Baqui AH.

Vaccine. 2011 Feb 1;29(6):1347-54. doi: 10.1016/j.vaccine.2010.10.035. Epub 2010 Oct 30.

PMID:
21040694
[PubMed - indexed for MEDLINE]
12.

Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.

Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, Sela T, Kayouf R, Klein Z, Ambar R, Cohen D, Wolf MK, Venkatesan MM, Hale TL.

Infect Immun. 2005 Dec;73(12):8027-32.

PMID:
16299296
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.

Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.

Vaccine. 2011 Sep 16;29(40):7009-19. doi: 10.1016/j.vaccine.2011.07.033. Epub 2011 Jul 23.

PMID:
21787825
[PubMed - indexed for MEDLINE]
14.

Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.

Barry EM, Wang J, Wu T, Davis T, Levine MM.

Vaccine. 2006 May 1;24(18):3727-34. Epub 2005 Jul 22.

PMID:
16169130
[PubMed - indexed for MEDLINE]
15.

Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.

Noriega FR, Wang JY, Losonsky G, Maneval DR, Hone DM, Levine MM.

Infect Immun. 1994 Nov;62(11):5168-72.

PMID:
7927802
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys.

Kärnell A, Cam PD, Verma N, Lindberg AA.

Vaccine. 1993;11(8):830-6.

PMID:
8356844
[PubMed - indexed for MEDLINE]
18.

Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL.

Vaccine. 2008 Jun 19;26(26):3291-6. doi: 10.1016/j.vaccine.2008.03.079. Epub 2008 Apr 16.

PMID:
18468742
[PubMed - indexed for MEDLINE]
19.

Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine.

Noriega FR, Losonsky G, Lauderbaugh C, Liao FM, Wang JY, Levine MM.

Infect Immun. 1996 Aug;64(8):3055-61.

PMID:
8757833
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Kotloff KL, Herrington DA, Hale TL, Newland JW, Van De Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM.

Infect Immun. 1992 Jun;60(6):2218-24.

PMID:
1587589
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk